Almitas Capital LLC Acquires 1,432,086 Shares of Lyell Immunopharma, Inc. $LYEL

Key Points

• Almitas Capital LLC increased its stake in Lyell Immunopharma by 136.3% during the first quarter, owning 2,482,606 shares worth $1.336 million.
• Lyell Immunopharma reported a quarterly earnings per share of ($2.89), surpassing the consensus estimate, while showing a negative return on equity of 85.58%.
• Research analysts have mixed opinions on the stock, with one upgrading it to a "hold" and a consensus price target of $15.00, while it currently trades at around $11.41.

Almitas Capital LLC lifted its holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 136.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,482,606 shares of the company's stock after purchasing an additional 1,432,086 shares during the period. Almitas Capital LLC owned 0.84% of Lyell Immunopharma worth $1,336,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. Foresite Capital Management V LLC bought a new position in shares of Lyell Immunopharma in the fourth quarter worth about $5,205,000. venBio Partners LLC acquired a new stake in Lyell Immunopharma during the fourth quarter worth about $4,545,000. Jacobs Levy Equity Management Inc. acquired a new stake in Lyell Immunopharma during the fourth quarter worth about $887,000. D. E. Shaw & Co. Inc. grew its position in Lyell Immunopharma by 104.4% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 966,265 shares of the company's stock worth $618,000 after buying an additional 493,639 shares in the last quarter. Finally, Millennium Management LLC grew its position in Lyell Immunopharma by 34.8% during the fourth quarter. Millennium Management LLC now owns 957,507 shares of the company's stock worth $613,000 after buying an additional 247,440 shares in the last quarter. 66.05% of the stock is currently owned by institutional investors.

Lyell Immunopharma Stock Performance

NASDAQ LYEL traded up $0.43 during trading on Friday, reaching $12.15. 18,409 shares of the company traded hands, compared to its average volume of 26,417. The stock's 50 day moving average price is $10.67 and its two-hundred day moving average price is $10.35. The company has a market cap of $233.40 million, a price-to-earnings ratio of -0.50 and a beta of -0.19. Lyell Immunopharma, Inc. has a 1-year low of $7.65 and a 1-year high of $32.00.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($2.89) earnings per share for the quarter, beating analysts' consensus estimates of ($3.80) by $0.91. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Lyell Immunopharma had a negative return on equity of 85.58% and a negative net margin of 552,328.31%. Equities research analysts expect that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Analyst Ratings Changes

LYEL has been the topic of a number of recent research reports. HC Wainwright reissued a "neutral" rating and set a $10.00 target price on shares of Lyell Immunopharma in a research report on Tuesday, June 24th. Wall Street Zen raised Lyell Immunopharma from a "sell" rating to a "hold" rating in a research report on Monday, September 1st. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Reduce" and an average target price of $15.00.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.